Shares of Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) dropped 2.4% during mid-day trading on Tuesday . The company traded as low as $5.09 and last traded at $5.22. Approximately 201,944 shares changed hands during trading, a decline of 27% from the average daily volume of 275,680 shares. The stock had previously closed at $5.35.
Analyst Ratings Changes
Separately, Wall Street Zen cut shares of Dominari from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Check Out Our Latest Stock Analysis on Dominari
Dominari Stock Performance
The firm has a market capitalization of $78.91 million, a P/E ratio of -1.20 and a beta of 0.61. The stock's 50 day simple moving average is $5.24 and its 200 day simple moving average is $4.81.
Dominari (NASDAQ:DOMH - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $0.20 earnings per share for the quarter. Dominari had a negative net margin of 167.73% and a negative return on equity of 91.67%. The firm had revenue of $6.56 million during the quarter.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of DOMH. Renaissance Technologies LLC increased its stake in shares of Dominari by 20.0% in the fourth quarter. Renaissance Technologies LLC now owns 56,326 shares of the company's stock worth $55,000 after acquiring an additional 9,400 shares during the period. PFG Investments LLC acquired a new stake in Dominari during the first quarter valued at $566,000. Finally, Magnus Financial Group LLC acquired a new stake in Dominari during the second quarter valued at $136,000. Institutional investors and hedge funds own 42.48% of the company's stock.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Read More
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
